Phihong Technology Co Ltd (2457 TW) stock market data APIs
NT$20.2383
-0.62(-3.1%)
as of July 11, 2025
Try our APIs with
free plan!
Phihong Technology Co Ltd Financial Data Overview
Price chart is built with
Anychart
Phihong Technology Co., Ltd. engages in the research and development, design, manufacture, and sale of power supply products in Taiwan. The company operates through Power Supply Unit, Electric Vehicle Energy, and Other segments. It offers adapters, including interchangeable AC pin, USB Type C, quick charger, foldable AC pin, car charger, desktop, and medical grade adapter; PoE comprising injector, splitter, extender, accessories, and redundant power source; and AC and DC chargers, charging modules. The company also offers job-site radio and e-motive chargers, such as li-ion and lead-acid series. The company was formerly known as Phihong Enterprise Co., Ltd. and changed its name to Phihong Technology Co., Ltd. in June 2003. Phihong Technology Co., Ltd. was incorporated in 1972 and is based in Taoyuan City, Taiwan.
Prev. Close
20.2383
Open
19.619
High
20.4726
Low
19.619
52 wk Range
19.6-49.25
Market Cap
8 644 M
Shares Outstanding
425 M
Revenue
10 814 M
EPS
0.3137
Beta
0.749
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phihong Technology Co Ltd data using free add-ons & libraries
Get Phihong Technology Co Ltd Fundamental Data
Phihong Technology Co Ltd Fundamental data includes:
- Net Revenue: 10 814 M
- EBITDA: -82 192 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phihong Technology Co Ltd News
New
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild CO...
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild CO...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
